ELMO2

Across TCGA pan-cancer cohorts, ELMO2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ELMO2 data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher ELMO2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ELMO2 expression acts as an unfavorable survival marker.

LIHC, ACC, and HNSC are the cancer types where ELMO2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	II,III,IV	0.118	0.716	.003	18	view →
ACC	DFS	Median	All	0.089	0.666	.017	6	view →
HNSC	OS	Median	II,III,IV	0.222	0.710	.031	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	II,III,IV	0.192	0.707	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ELMO2–LIHC (OS)

Open the LIHC breakdown →